Pixee wins FDA clearance for Knee+ NexSight AR knee platform

Pixee Medical said it has received U.S. FDA 510(k) clearance for Knee+ NexSight, an augmented reality guidance system for total knee arthroplasty. The France-based company is positioning the platform for U.S. ambulatory surgery centers, saying the new version is lighter, more compact, compatible with primary knee implants, and designed to fit existing workflows without a robot, dedicated console, or preoperative imaging. The clearance follows a CE mark announced on March 24, 2026, after which Pixee said more than 20 procedures had already been performed across France and Belgium by six surgeons. (businesswire.com)

Why it matters: While this is a human orthopedics story rather than a veterinary device launch, it’s still relevant to veterinary professionals tracking surgical navigation trends. Pixee is making the case that augmented reality can deliver more precise implant positioning without the footprint and capital demands of robotic systems, a message likely to resonate in cost-sensitive surgical settings. The company also points to prior clinical evidence around its Knee+ platform, including a 2024 Arthroplasty Today study and earlier FDA clearances for Knee+, suggesting this latest nod builds on an established regulatory and clinical base rather than a first-time concept. (businesswire.com)

What to watch: Watch for details on U.S. commercial rollout, ASC adoption, and whether Pixee publishes more peer-reviewed outcomes data specific to NexSight. (businesswire.com)